Evidence map›Paper›PMID 28929327›Full record

ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2017

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized Controlled Pilot Trial (SPAN-S).

Takuya Awata, Akira Shimada, Taro Maruyama, Yoichi Oikawa, Nobuyuki Yasukawa, Susumu Kurihara, Yumi Miyashita, Masako Hatano, Yuichi Ikegami, Masafumi Matsuda and 4 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05219409 (Effects of Sitagliptin in Relatives of Patients With Type 1 Diabetes Mellitus, at High Risk of Developing the Disease), which is not on this map. Cited by 30 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 3 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05219409 phase2 / phase3not yet recruitingnot on this mapstarted 2023, after this paper: background citation

Effects of Sitagliptin in Relatives of Patients With Type 1 Diabetes Mellitus, at High Risk of Developing the Disease

TypeinterventionalSponsorUniversity of MilanRan2023 to 2027Enrolled70ConditionsType 1 DiabetesArmsSitagliptin, Professional CGM
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 3 syntheses or guidelines pooled it, 54 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Latent autoimmune diabetes in youth.Frontiers in immunology · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Efficacy of Regimens in the Treatment of Latent Autoimmune Diabetes in Adults: A Network Meta-analysis.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  16. Adult-onset autoimmune diabetes.Nature reviews. Disease primers · 2022
    Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Takuya AwataDepartment of Diabetes, Endocrinology and Metabolism, International University of Health and Welfare Hospital, Iguchi, Nasushiobara-shi, Tochigi, Japan. awatatakuya@gmail.com.ORCID http://orcid.org/0000-0003-2622-8129
Akira ShimadaDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Taro MaruyamaDepartment of Internal Medicine, Saitama Social Insurance Hospital, Saitama, Japan.
Yoichi OikawaDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Nobuyuki YasukawaDepartment of Diabetes, Endocrinology and Metabolism, International University of Health and Welfare Hospital, Iguchi, Nasushiobara-shi, Tochigi, Japan.
Susumu KuriharaDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Yumi MiyashitaDivision of RI Laboratory, Biomedical Research Center, Saitama Medical University, Saitama, Japan.
Masako HatanoDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Yuichi IkegamiDepartment of Endocrinology and Diabetes, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
Masafumi MatsudaDepartment of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Masataka NiwaIidabashi Medical Clinic, Tokyo, Japan.
Youichiro KazamaKazama Medical Clinic, Yamanashi, Japan.
Shoichiro TanakaAi Home Clinic Toshima, Tokyo, Japan.
Tetsuro KobayashiDivision of Immunology and Molecular Medicine, Okinaka Memorial Institute for Medical Research, Tokyo, Japan.
Saitama Medical University · JPInternational University of Health and Welfare · JPSocial Insurance Saitama Chuo Hospital · JPOsaka Nishi Clinic · JPToshima Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionWe tested the hypothesis that dipeptidyl peptidase-4 (DPP-4) inhibitors are effective in preserving the β-cell function for long-term periods in patients with slowly progressive type 1 diabetes (SPIDDM) or latent autoimmune diabetes in adults (LADA).

methodsIn the present open-label, randomized, controlled trial, 14 non-insulin-requiring diabetic patients with glutamic acid decarboxylase autoantibodies (GADAb) were randomly assigned to receive either sitagliptin (S group) or pioglitazone (P group). As a historical control, the Tokyo Study, in which non-insulin-dependent patients with SPIDDM were assigned to receive treatment by either insulin or sulfonylurea (SU), was used.

resultsOn average, the ∑C-peptide values during the oral glucose tolerance test through the follow-up periods showed a nonsignificant increase in the S group (n = 6, n = 5 at 48 months) compared to the P group (n = 5, n = 2 at 48 months). In comparison to the data in the Tokyo Study, treatment by sitagliptin significantly influenced the longitudinal changes in the ∑C-peptide values with a more increased direction than insulin or SU, especially in patients with 48 months of follow-up (p = 0.014 and p = 0.007, respectively). Although the titers of GADAb were not significantly different between the S and P groups during the study, the change ratio of the GADAb titers from baseline was significantly inversely correlated with the change ratio of the ∑C-peptide values from baseline in the S group (p = 0.003); in particular, when the GADAb titers decreased from baseline, the ∑C-peptide values frequently increased.

conclusionThe present pilot trial suggests that treatment of SPIDDM/LADA by sitagliptin, a DPP-4 inhibitor, may be more effective in preserving the β-cell function than insulin treatment for at least 4 years, possibly through the immune modulatory effects of DPP-4 inhibitors. CLINICAL

trial registrationJapanese Clinical Trials Registry UMIN000003693.

Indexed as

Dipeptidyl peptidase-4 (DPP-4) inhibitorInterventionLatent autoimmune diabetes in adults (LADA)PreventionSitagliptinSlowly progressive type 1 diabetes (SPIDDM)Type 1 diabetes

Identifiers

PMID28929327
PMCPMC5630555
OpenAlexW2754426117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.